Appleton Partners’s Impax Laboratories, Inc. IPXL Stock Holding History

Appleton Partners’s Portfolio IPXL Stock Details IPXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-11,845	Closed	-$191K	–	255
2017 Q2	$191K	Buy	+11,845	New	+$175K	0.03%	239

Other funds holding IPXL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Appleton Partners's IPXL Position: Q3 2017 in Review

Appleton Partners sold out of Impax Laboratories, Inc. (IPXL) in Q3 2017, closing a stake of 11,845 shares — an estimated $191K sold.

Appleton Partners first reported a position in IPXL in Q2 2017 and held it in 1 quarter. The position peaked at $191K in Q2 2017. 189 funds tracked by Wall St. Rank hold IPXL as of Q3 2017.

Appleton Partners reported no remaining Impax Laboratories, Inc. position as of Q3 2017 after selling out during the quarter.
Appleton Partners sold 11,845 Impax Laboratories, Inc. shares in Q3 2017, an estimated $191K.
Appleton Partners first reported a position in Impax Laboratories, Inc. in Q2 2017 and held it in 1 quarter.
Appleton Partners's Impax Laboratories, Inc. position peaked at $191K in Q2 2017.
189 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q3 2017.

Based on Appleton Partners's 13F filing for Q3 2017, filed 12 Oct 2017.